Blar i forfatter "Jensvoll, Hilde"

Viser treff 1-6 av 6

    • Cancer and venous thromboembolism 

      Jensvoll, Hilde (Doctoral thesis; Doktorgradsavhandling, 2015-10-02)
      Venøs tromboembolisme (VTE) er et samlebegrep for lungeemboli og dyp venetrombose. VTE rammer ofte kreftpasienter og representerer en ledende dødsårsak i denne pasient gruppen. Dette understreker viktigheten av å kartlegge risikofaktorer for kreft-relatert VTE for å muliggjøre forebyggende behandling hos pasienter med høy risiko. En VTE hendelse kan også være det første symptomet på en bakenforliggende ...

    • Existing data sources in clinical epidemiology: The Scandinavian Thrombosis and Cancer Cohort 

      Jensvoll, Hilde; Severinsen, Marianne T.; Hammerstrøm, Jens; Brækkan, Sigrid Kufaas; Kristensen, Søren R.; Cannegieter, Suzanne C.; Blix, Kristine; Tjønneland, Anne; Rosendaal, Frits Richard; Dziewiecka, Olga; Overvad, Kim; Næss, Inger Anne; Hansen, John-Bjarne (Journal article; Tidsskriftartikkel; Peer reviewed, 2015-09-16)
      Background: Although venous thromboembolism (VTE) is a known common complication in cancer patients, there is limited knowledge on patient-related and cancer-specific risk factors in the general population. The Scandinavian Thrombosis and Cancer (STAC) Cohort was established by merging individual data from three large Scandinavian cohorts (The Tromsø Study, the second Nord-Trøndelag Health Study, ...

    • Joint effects of cancer and variants in the factor 5 gene on the risk of venous thromboembolism 

      Gran, Olga Vikhammer; Smith, Erin N.; Brækkan, Sigrid Kufaas; Jensvoll, Hilde; Solomon, Terry; Hindberg, Kristian; Wilsgaard, Tom; Rosendaal, Frits Richard; Frazer, Kelly A.; Hansen, John-Bjarne (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-09)
      Venous thromboembolism occurs frequently in cancer patients. Two variants in the factor 5 gene (F5), rs6025 encoding for the factor V Leiden mutation R506Q, and rs4524 encoding K858R, have been found to be associated with venous thromboembolism. We assessed the joint effect of active cancer and these two F5 variants on venous thromboembolism risk in a case-cohort study. Cases with a first venous ...

    • Platelet Count Measured Prior to Cancer Development Is a Risk Factor for Future Symptomatic Venous Thromboembolism: The Tromsø Study 

      Jensvoll, Hilde; Blix, Kristine; Brækkan, Sigrid Kufaas; Hansen, John-Bjarne (Journal article; Tidsskriftartikkel; Peer reviewed, 2014-03-18)
      Background: Elevated platelet count is associated with risk of venous thromboembolism in cancer patients initiating chemotherapy. It is not known whether this risk by platelet count is causal or merely reflects the malignant disease. We investigated whether pre-cancer platelet count alone or together with high leukocyte count was associated with risk of venous thromboembolism in subjects who did and ...

    • Thromboembolic Events During Treatment with Cisplatin-based Chemotherapy in Metastatic Testicular Germ-cell Cancer 2000–2014: A Population-based Cohort Study 

      Haugnes, Hege S.; Negaard, Helene F.; Negaard, Helene Francisca Stigter; Jensvoll, Hilde; Wilsgaard, Tom; Tandstad, Torgrim; Solberg, Arne (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-08-15)
      <i>Background</i> - Cisplatin-based chemotherapy (CBCT) in testicular cancer (TC) is associated with elevated venous thromboembolism (VTE) risk, but trials evaluating the safety and efficacy of thromboprophylaxis are lacking.<br><br> <i>Objective</i> - To evaluate the arterial thromboembolism (ATE) and VTE incidence and risk factors during first-line CBCT for metastatic TC, and the effect of ...

    • White blood cell count measured prior to cancer development is associated with future risk of venous thromboembolism - The Tromsø Study 

      Blix, Kristine; Jensvoll, Hilde; Brækkan, Sigrid Kufaas; Hansen, John-Bjarne (Journal article; Tidsskriftartikkel; Peer reviewed, 2013-09-04)
      Background: Elevated white blood cell (WBC) count is associated with risk of venous thromboembolism (VTE) in cancer patients initiating chemotherapy. It is not known whether the risk of VTE by WBC count in cancer patients is causal or merely a consequence of the malignant disease. To address this question, we studied the association between WBC count, measured prior to cancer development, and ...